TUCSON ORTHOPAEDIC RESEARCH CENTER
Research and science go hand-in-hand with a commitment to be on the leading edge of the medical profession. New developments in orthopaedics, pain management, soft tissue injuries, hematology concerns, and post-operative care are studied efficiently and at the highest level of quality at the Tucson Orthopaedic Research Center.
The focus of the Tucson Orthopaedic Research Center is phase II, III, and IV clinical protocols. Our clinical trial experience and therapeutic interests includes:
- Orthopaedic devices
- Acute and chronic pain (post-surgical)
- Acute and chronic back, neck and shoulder pain
- Rheumatoid arthritis
- Foot and Ankle
- Carpal tunnel syndrome
- Hip and knee disorders
- Soft tissue injuries
- Erythropoisesis stimulants
- Anti-inflammatory medications (COX-2 and other NSAIDs)
The Tucson Orthopaedic Research Center has worked with numerous pharmaceutical and biotechnology companies and CRO’s, including:
- AAI Pharma
- Algos Pharmaceuticals
- Bristol-Myers Squibb
- Careers in Research
- CATO Research
- ClinTrials Research Inc.
- DePuy (J&J) orthopaedics
- DePuy AcroMed (Johnson & Johnson)
- Eli Lilly
- Ferring Pharmaceutical
- Forest Laboratories Inc.
- ICON Clinical Research
- INC Research
- Johns Hopkins
- Johnson & Johnson
- Karl Storz
- Kendle International
- King Pharmaceutical
- Neurobiological Technologies Inc.
- Ortho Biotech
- Ortho McNeil
- Pharmaceutical Resource Corporation
- PRA International
- PPD Development
- Purdue Pharma
- Research Point
- Research Services, Inc.
- RS Medical Research Services Inc.
- SmithKline Beecham
- Smith & Nephew
- Stryker Howmedica
- TAP Pharmaceutical Products
- VQ OrthoCARE
Hip and Knee Osteoarthritis Study with Monoclonal Antibodies: (Protocols R475-PN-1523 and R475-OA-1611) A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo Controlled (and Naproxen-Controlled) Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients with Pain Due to Osteoarthritis of the Knee or Hip.
Knee Osteoarthritis Study with Hyaluronic Acid: (Protocol EQE7-16-01) A post-market, single blind, multicenter, randomized, controlled trial of HYMOVIS® intra-articular injections in active Subjects with knee osteoarthritis.
Articular Cartilage Lesions in Knee Study: (Protocol CLNA043X2202) A randomized, placebo-controlled, patient and investigator blinded, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of multiple intra-articular LNA043 injections in regenerating the articular cartilage of the knee in patients with articular cartilage lesions.
6/6/2018 – APS Injection for Knee OA
5/21/2018 – Injection of Gel-One® for the treatment of Osteoarthritis of the Knee
4/20/2018 – Injection for Moderate-to-Severe Chronic Low Back Pain in Osteoarthritis of the Hip or Knee
6/12/2017 – Titration Injection Regimen for Osteoarthritis of the Hip or Knee
9/27/2012 -Osteoarthritis of the Knee
9/4/2012 – Hip Osteoarthritis
7/9/2012 – Total Hip Replacement Clinical Research Study
11/4/2011 – Dupuytren’s Multiple Cords
9/4/2012 – Hand osteoarthritis
5/24/2012 – Frozen shoulder research study
6/29/2011 – Meniscectomy surgery
6/20/2011 – Investigating Superion in spinal stenosis
6/16/2011 – Foot and ankle surgery with new growth factor to facilitate bone fusion
6/14/2011 – Osteoarthritis of the knee – mild to moderate
6/9/2011 – Cartilage autograft implantation system (CAIS) for the repair of knee cartilage through cartilage regeneration
5/4/2011 – Assessment of long-term safety in patients with non-cancer-related pain and opioid-induced constipation
2/1/2011 – Influenza
8/16/2010 – Re-exposing Thrombin to patient during spine surgery to help control bleeding
8/15/2010 – Treatment for pain caused by tennis elbow with a medicated patch designed to release a specific amount of medication driven by electric current
8/14/2010 – Treatment for pain caused by a sprain with a medicated cream
8/13/2010 – The use of one’s own bone for an ankle fusion
8/12/2010 – An injection of a viscosupplement (HA) in to the knee to help control pain cause by osteoarthritis of the knee
8/11/2010 – The use of Recothrombin in patients who have already been exposed to Recothrombin having spine surgery to help control bleeding
8/10/2010 – Treatment for pain caused by an ankle sprain with a medicated patch
8/9/2010 – Treatment of pain caused by an ankle sprain with a medicated patch
8/8/2010 – A follow up on patients post Zimmer knee replacement
8/7/2010 – Intravenous infusion of an antibody to block pain caused by osteoarthritis of the knee and hip
8/6/2010 – Intravenous infusion of an antibody to block pain caused by osteoarthritis of the knee
8/5/2010 – An injection of a hyaluronic acid in to the knee to help control pain cause by osteoarthritis of the knee
8/2/2010 – Tennis elbow/ chronic elbow tendinitis
8/2/2010 – The use of Recothrombin in patients having spine surgery to help control bleeding
8/1/2010 – Injection of Xiaflex for patients with Dupuytren’s contracture
3/3/2010 – Moderate lumbar stenosis
Frequently Asked Questions
The Food and Drug Administration requires that clinical trials be conducted with investigational medications before it will approve their use with the general public. By conducting clinical trials and studies of investigational medication or investigational treatments, research centers help ensure that the investigational medication is effective and safe.
Each trial is unique. Often, clinical trials are sponsored by the company that makes the drug or device being studied. Sometimes, studies are paid for by government health agencies or research foundations looking to treat or cure a certain disease. The sponsor may pay for treatments, such as medication or examinations, necessary for the trial to occur. Also, the sponsor may pay participants for volunteering for the study.
Every clinical trial is designed to answer a set of research questions. If you fit the guidelines for a trial, you may be eligible to take part. Each study enrolls patients with specific types of injuries, illnesses, and/or certain health status. Before you and your physician make a decision about your treatment (whether it is in a clinical trial or not), your physician will consider many things such as the stage of the illness and your general health.
Often patients are referred to a trial by a doctor who knows your case. Some patients find out about trials from other sources as well, such as advertisements. In either scenario, you must have a reasonable understanding of your role in a research study and be freely willing to participate.
At the start of a trial, you will be given an informed consent form to sign. This is required by law. The consent form describes the purpose, procedures, benefits, risks, discomforts, and precautions of the study. Also, before any clinical trial can begin, it must be approved by an institutional review board (IRB). This is a group of doctors, scientists, patient advocates, legal representatives, and/or clergy who make sure there is a good scientific reason for the trial, and that risks to participants are balanced with the potential benefit.
Participation is confidential, except as required by law. The investigator for the trial may release your medical records to the sponsor and its representatives, and in certain circumstances, the FDA and the IRB. However, any publication of the data obtained in the study will not identify you by name.
Because clinical trials are research into new areas of treatment, the risks involved are not always known ahead of time, though extreme efforts have been taken to identify what possible side effects may occur. For this reason, trials can carry unknown dangers and side effects as well as hoped-for benefits.
Patients need to know what is involved in a study, what side effects may be expected, and, as much as possible, what unknowns or uncertainties they may be facing. Side effects will often vary from patient to patient. Your doctor or research nurse will inform you about the treatments being tested and provide you with information that discusses the risks and hoped-for benefits of the clinical trial.
If you agree to take part, you will be asked to sign a form, called an informed patient consent. Before you sign, ask the doctor or nurse to explain any part(s) of the form or the trial that are unclear to you.
Generally, you will be asked to complete visits with the physician or study manager as scheduled, take the medication as directed, and you may be asked to write down how you feel throughout the course of the study. You will be asked to contact the study coordinator at any time if you are hospitalized for any reason. You are, however, free to leave the study at any time.
Clinical trials are carried out in phases, each designed to find out certain information. Patients may be eligible for studies in different phases depending on their general condition and the type and stage of their illness.
In a Phase I study, a new research treatment is given to a small number of patients. The researchers must find the best way to give a new treatment and how much of it can be given safely, watching carefully for any harmful side effects. By this point, the research treatment has been well-tested in laboratory and animal studies, but very little information is available how human patients will respond.
Phase II studies determine the effect of a research treatment on various types of illnesses. Each new phase of a clinical trial depends on and builds on information from an earlier phase. If a treatment has shown activity against a particular illness in Phase II, it moves to Phase III. Here it is compared to the standard method of treatment to see which is more effective.
Often researchers use standard therapy as the base to design new and hopefully better treatments. Then in Phase III, the new treatment is directly compared to the standard treatment. In Phase IV studies, the new research treatment becomes part of standard treatment in patient care.
The Institute carefully screens each proposal it receives, and accepts about one in each dozen opportunities to conduct research. The Research Center has completed studies for Merck, Pfizer, Novartis, Amgen, Bristol-Myers Squib, Bayer, Astra-Zeneca, DePuy, Stryker, and Zimmer, among others. The resources from the sponsors allow the doctors to more fully develop their specialties and provide a method to independently determine which treatment option is really best for each individual patient.
Participants are qualified for studies by detailed criteria. Above all, they must understand potential benefits and risks, which is carefully explained. Prospective participants are interviewed to determine their potential for following through on all the requirements. If you would like to participate in a study or trial, please contact Tucson Orthopaedic Institute at (520) 784-6200 and ask for the Research Department.
Federal safety standards, developed and monitored by the Federal Food and Drug Administration (FDA) are rigorously applied. Privately run trials must pass scrutiny of the Human Subjects Committees, which make sure that patients will not be exploited; Contract Research Organizations (CROs) hired by the sponsor to monitor the research site; and Site Management Organizations (SMOs), independent contractors, looking for sites around the country and managing them during the study.
The Tucson Orthopaedic Research Center is directed by a licensed medical doctor, with over ten years of experience in research and the oversight of clinical trials. This physician is dedicated full time to the Research Center and is supported by experienced, licensed registered nurses who are certified as research coordinators by the Association of Clinical Research Professionals (ACRP).